 
Stromedix raises $25 million in a Series B financing round
MORE (PDF) >
Stromedix profiled in BioCentury in October, 2007
MORE (PDF) >
Corporate Factsheet
Download our Corporate
Factsheet for information on who we are and what we do.
DOWNLOAD (PDF) >
|
|
Stromedix, Inc.
One Canal Park, Suite 1120
Cambridge MA 02141
tel 617.674.8400
fax 617.674.8390
info@stromedix.com
To learn more about Stromedix, please send your resume to hr@stromedix.com. Stromedix is an equal opportunity employer.
| |
 
STX-100 is Stromedix’ first clinical candidate and is being developed for the treatment of chronic allograft dysfunction in kidney transplant recipients.
 |
Humanized monoclonal antibody to integrin αvβ6 |
|
Set to enter phase 1 clinical testing in early 2008 |
|
In-licensed from Biogen Idec in 2007 |
|
Provides localized, injury-specific inhibition of TGF-β activation
|
|
Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease |
|
Broad therapeutic utility in chronic organ failure, acute organ failure and cancer |
|
